The Weill Cornell Medicine Pediatric Nephrology team focuses on a wide range of research activities to expand the understanding of renal and other nephrology disorders in children and adolescents, and to develop new strategies for the prevention and management of renal disease and injury. We continue to break new ground in our understanding of conditions including chronic kidney disease, kidney transplant outcomes and hemolytic uremic syndrome.
Juhi Kumar, M.D. is the recipient of a career development award from the NIDDK, to evaluate the role of vitamin D and Fibroblast Growth Factor 23 (FGF23) in growth and CKD progression, in the largest study of children with CKD in North America. Her recent publications deal with the prevalence and determinants of vitamin D deficiency, secondary hyperparathyroidism and fractures in the CKD cohort.
Juhi Kumar, M.D. is the recipient of a CTSC pilot grant to evaluate markers of allograft damage in blood and urine, as well as the gut microbiome, in pediatric kidney transplant recipients both with and without donor-specific antibodies. In addition, she will explore the relationship of these markers and the gut microbiome with vitamin D and Fibroblast Growth Factor 23 (FGF23).
Oleh Akchurin, M.D., Ph.D. conducts this analysis of CKD longitudinal data, evaluating the relationship of inflammatory and mineral metabolism markers with growth, in order to identify novel predictors of poor growth in children with CKD, including inflammatory mediators. He approaches the research utilizing a dietary mouse model of growth delay in juvenile CKD based on an 0.2 percent adenine diet. This model enable investigation of mechanisms that may be involved in growth delay in juvenile CKD, as well as utilization of approaches that cannot be easily applied in children, including bone micro-CT. This model will also be used to test novel therapeutic strategies targeting growth and nutrition.
Eduardo Perelstein, M.D., M.P.H. is the site principal investigator for an observational, multicenter study analyzing patients with atypical Hemolytic Uremic Syndrome (HUS), sponsored by Alexion Pharmaceuticals.